Next-Generation Psychedelic Drug Development
Lindsay P. Cameron, Matthew W. Johnson, Kevin S. Murnane, M. Rasenick, Charles D. Nichols
ACS Chemical Neuroscience September 15, 2026 DOI: 10.1021/acschemneuro.6c00492 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The authors review assays and models used in psychedelic drug development, weighing their strengths and limitations, and propose guidance for developing next-generation psychedelic therapies for neuropsychiatric disorders including depression, anxiety, and post-traumatic stress disorder. |
Abstract
Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.